Biotech Stocks To Buy Based on Artificial Intelligence: Returns up to 10.72% in 3 Days
Package Name: BioTech StocksRecommended Positions: Short
Forecast Length: 3 Days (10/19/2018 - 10/22/2018)
I Know First Average: 3.56%
Read The Full Forecast
Package Name: BioTech StocksRecommended Positions: Short
Forecast Length: 3 Days (10/19/2018 - 10/22/2018)
I Know First Average: 3.56%
Biotech Stocks To Watch Based on Big Data Analytics: Returns up to 50.60% in 14 Days
Package Name: BioTech StocksRecommended Positions: Long
Forecast Length: 14 Days (09/18/2018 - 10/03/2018)
I Know First Average: 8.80%
Read The Full Forecast
Biotech Stocks To Buy Based on Predictive Analytics : Returns up to 45.65% in 14 Days
Package Name: BioTech StocksRecommended Positions: Long
Forecast Length: 14 Days (09/18/2018 - 10/02/2018)
I Know First Average: 7.76%
Read The Full Forecast
Biotechnology Stocks To Watch Based on Stock Algorithm: Returns up to 49.78% in 14 Days
Package Name: BioTech StocksRecommended Positions: Long
Forecast Length: 14 Days (09/17/2018 - 10/01/2018)
I Know First Average: 16.21%
Read The Full Forecast
Biotech Stocks To Buy Based on Stock Prediction Algorithm: Returns up to 49.57% in 14 Days
Package Name: BioTech StocksRecommended Positions: Long
Forecast Length: 14 Days (09/16/2018 - 09/30/2018)
I Know First Average: 15.91%
Read The Full Forecast
Biotechnology Stocks To Buy Based on Deep Learning: Returns up to 52.38% in 7 Days
Package Name: BioTech StocksRecommended Positions: Long
Forecast Length: 7 Days (09/18/2018 - 09/25/2018)
I Know First Average: 15.69%
Read The Full Forecast
Winning Stock Forecast: Acadia, Protalix Bring Big Returns In The BioTech Space
ACAD Winning Stock Forecast
By Pöllö -commons.wikimedia.org
This week ACAD saw a 52.38% jump, being the 7 day forecast’s biggest earner, as the I Know First algorithm predicted. Before this week, ACAD’s shares have been under pressure from what turned out to be an inaccurate report from CNN. Acadia Pharmaceuticals is again bringing in impressive returns. The drug under fire was Nuplazid. The FDA only recently discarded these allegations to be untrue. Nuplazid made up $57.1 million in sales Q2 for ACAD, an 18% increase from the first quarter. Sales of the drug are increasing 87% year over year. The
We Are UBS Regional Finalist
We Are A FinTech Awards Finalist
Start Algorithmic Trading Today!
Gold & Commodity Forecasts
Currency Forecasts
Subscribe To The I Know First Newsletter
